Diabetes patients can be a target for chronic kidney disease but can also take aim back: This is the message from AstraZeneca’s new Farxiga TV ad, which is pushing the drug’s new CKD label.

AstraZeneca has watched superstar SGLT2 diabetes med Farxiga nail trial after trial in highly coveted kidney and heart failure indications, with the FDA expediting reviews to back them up.

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the results of DERIVE, a Phase 3 study that evaluated the efficacy and safety of FARXIGA ® (dapagliflozin 10 mg), in patients with ...

AstraZeneca now has 16 blockbuster medicines in its portfolio with sales (product sales and alliance revenues) exceeding $1 ...

AstraZeneca's blockbuster diabetes drug Farxiga led to significant reductions in the risk of hospitalisation and death in people with all types of heart failure, according to study data released ...

AstraZeneca's Farxiga reduced the risk of hospitalisation and death in people with all types of heart failure in the DELIVER trial, which could dramatically increase the population of patients ...

British drugmaker AstraZeneca Plc said on Tuesday that its diabetes drug Farxiga was successful in reducing the risk of death by heart attack or the worsening of a type of heart failure in a late ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s FARXIGA ® (dapagliflozin) has been approved by the US Food and Drug Administration (FDA) to improve glycemic control in pediatric patients with ...

AstraZeneca achieved record revenue growth of 18% in 2024, driven by key products like Farxiga and Tagrisso, and numerous regulatory approvals. The company’s diversified portfolio spans oncology ...

AstraZeneca AZN announced that the FDA has issued a complete response letter ("CRL") to its supplemental new drug application (sNDA) for SGLT2 inhibitor, Farxiga (dapagliflozin).

AstraZeneca PLC said Monday that a Phase 3 trial to assess the potential of its Farxiga diabetes drug to treat patients with Covid-19 at risk of developing serious complications didn't achieve ...